By: Khilna Patel, Pharm.D. Candidate c/o 2012 – On October 25 of this year, Eli Lilly and Company announced a worldwide market withdrawal of Xigris (drotrecogin alfa), a drug previously indicated to treat severe sepsis in high-risk patients.  Drotrecogin alfa is a recombinant form of human activated protein C.  The efficacy of drotrecogin alfa was…